Herzfeld Credit Income Fund, Inc. To Conduct a Tender Offer for up to 5% of Outstanding Common Shares

Evaxion A/S reported 3-year phase 2 data for EVX-01 in advanced melanoma, showing 89% target precision, immune responses in all patients, and no tumor progression in monotherapy patients. The data will be presented at ESMO 2026. According to the company, the results support its AI-Immunology platform and EVX-01's potential efficacy.

Evaxion A/S (NASDAQ: EVAX) reported three-year data from its phase 2 trial of EVX-01, a personalized cancer vaccine for advanced melanoma. All six patients in the trial's extension showed no tumor progression, maintaining responses seen at two years. The data will be presented at ESMO 2026. EVX-01 induced an immune response in all patients, with 89% of vaccine neoantigens generating potent T-cell responses.

CBRE reports 80% of North American data center capacity under construction is pre-leased, up from 74% a year earlier. Bitdeer (BTDR) secured $2.9B in AI cloud revenue backlog, with commitments for facilities in Malaysia and Norway. The company follows a strategy of contracting demand before developing capacity, with long-term leases and prepayments.

SeaStar Medical (ICU) reported higher survival rates in pediatric kidney injury patients treated with QUELIMMUNE. The analysis compared 43 treated patients to 196 historical cases, showing 65.1% survival at day 90 vs. 47.4%. No device-related adverse events were reported. ICU shares closed at $2.85, up 3.51% after-hours.

Nvidia has over $170 billion in commitments to support neocloud data center providers, including guarantees and investments. Recent market volatility has affected neocloud stocks, raising questions about Nvidia's exposure. Nvidia's CFO stated the risk is manageable, but the company is reportedly adjusting terms and exploring further investments. Neoclouds represent 45% of Nvidia's data center revenue, highlighting their strategic importance.

Lockheed Martin and Avio have agreed to expand US solid rocket motor production, focusing on ER GMLRS and PrSM missiles. Avio will invest $500M in a Virginia facility to support Lockheed Martin's programs, aiming to strengthen the defense supply chain and meet growing demand.